Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Terminated
The AVP-786 program was discontinued, the recruitment was stopped and all participants are no longer being examined or receiving intervention.
Other terminated trials from Otsuka Pharmaceutical Development & Commercialization, Inc.
- Agitation in Patients With Dementia of the Alzheimer's Type · Phase PHASE3 · Sep 2024
- Agitation in Patients With Dementia of the Alzheimer's Type · Phase PHASE3 · Jun 2024
- Schizophrenia · Phase PHASE3 · Nov 2023
- Schizophrenia · Phase PHASE2/PHASE3 · May 2023
- Healthy Volunteers · Phase PHASE1 · Nov 2022
More terminations from Otsuka Pharmaceutical Development & Commercialization, Inc.
Other Agitation in Patients With Dementia of the Alzheimer's Type trials with similar outcome
Browse all Agitation in Patients With Dementia of the Alzheimer's Type trials
This PHASE3 trial investigates Agitation in Patients With Dementia of the Alzheimer's Type and is currently terminated or withdrawn. Otsuka Pharmaceutical Development & Commercialization, Inc. leads this study, which shows 40 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
40 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Terminated PHASE3
-
Feb 2025 — Jun 2025 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Nov 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE3
▶ Show 35 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Apr 2024 — Jun 2024 [monthly]
Recruiting PHASE3
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE3
-
Sep 2023 — Feb 2024 [monthly]
Recruiting PHASE3
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE3
-
May 2023 — Jul 2023 [monthly]
Recruiting PHASE3
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE3
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE3
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Jan 2022 — Mar 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Oct 2021 — Dec 2021 [monthly]
Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE3
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE3
-
Aug 2020 — Oct 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE3
-
Jun 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Otsuka Pharmaceutical Development & Commercialization, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .